Dementia and psychotropic medications are associated with significantly higher mortality in geriatric patients hospitalized with COVID-19: data from the StockholmGeroCovid project
- PMID: 36609457
- PMCID: PMC9817345
- DOI: 10.1186/s13195-022-01154-w
Dementia and psychotropic medications are associated with significantly higher mortality in geriatric patients hospitalized with COVID-19: data from the StockholmGeroCovid project
Abstract
Background: Dementia and psychotropic medications are discussed as risk factors for severe/lethal outcome of the coronavirus disease 2019 (COVID-19). We aimed to explore the associations between the presence of dementia and medication use with mortality in the hospitalized and discharged patients who suffered from COVID-19.
Methods: We conducted an open-cohort observational study based on electronic patient records from nine geriatric care clinics in the larger Stockholm area, Sweden, between February 28, 2020, and November 22, 2021. In total, we identified 5122 hospitalized patients diagnosed with COVID-19, out of which 762 (14.9%) patients had concurrent dementia and 4360 (85.1%) were dementia-free. Patients' age, sex, baseline oxygen saturation, comorbidities, and medication prescription (cardiovascular and psychotropic medication) were registered at admission. The hazard ratios (HRs) with 95% confidence intervals (CIs) of in-hospital, 30-day, 90-day, 365-day post-discharge, and overall mortality during the follow-up were obtained. Then, the associations of dementia and medication use with mortality were determined using proportional hazards regression with time since entry as a time scale.
Results: After adjustment, dementia was independently associated with 68% higher in-hospital mortality among COVID-19 patients compared to patients who were dementia-free at admission [HRs (95% CI) 1.68 (1.37-2.06)]. The increase was consistent post-discharge, and the overall mortality of dementia patients was increased by 59% [1.59 (1.40-1.81)]. In addition, the prescription of antipsychotic medication at hospital admission was associated with a 70% higher total mortality risk [1.70 (1.47-1.97)].
Conclusions: The clinical co-occurence of dementia and COVID-19 increases the short- and long-term risk of death, and the antipsychotics seem to further the risk increase. Our results may help identify high-risk patients in need of more specialized care when infected with COVID-19.
Keywords: Antipsychotics; COVID-19; Dementia; Mortality.
© 2023. The Author(s).
Conflict of interest statement
The authors declare that they have no competing interests.
Figures
Similar articles
-
Exposure to psychotropic medications and COVID-19 course after hospital admission: Results from a prospective cohort study.J Psychosom Res. 2023 Apr;167:111199. doi: 10.1016/j.jpsychores.2023.111199. Epub 2023 Feb 18. J Psychosom Res. 2023. PMID: 36827888 Free PMC article.
-
New psychotropic medication use among Medicare beneficiaries with dementia after hospital discharge.J Am Geriatr Soc. 2023 Apr;71(4):1134-1144. doi: 10.1111/jgs.18161. Epub 2022 Dec 13. J Am Geriatr Soc. 2023. PMID: 36514208 Free PMC article.
-
Consensus and evidence-based medication review to optimize and potentially reduce psychotropic drug prescription in institutionalized dementia patients.BMC Geriatr. 2019 Jan 8;19(1):7. doi: 10.1186/s12877-018-1015-9. BMC Geriatr. 2019. PMID: 30621606 Free PMC article.
-
Mortality risk in patients with dementia treated with antipsychotics versus other psychiatric medications.Am J Psychiatry. 2007 Oct;164(10):1568-76; quiz 1623. doi: 10.1176/appi.ajp.2007.06101710. Am J Psychiatry. 2007. PMID: 17898349
-
Using antipsychotic agents in older patients.J Clin Psychiatry. 2004;65 Suppl 2:5-99; discussion 100-102; quiz 103-4. J Clin Psychiatry. 2004. PMID: 14994733 Review.
Cited by
-
Predictors of COVID‑19‑associated mortality among hospitalized elderly patients with dementia.Exp Ther Med. 2023 Jul 3;26(2):395. doi: 10.3892/etm.2023.12094. eCollection 2023 Aug. Exp Ther Med. 2023. PMID: 37456163 Free PMC article.
-
Outpatient Antipsychotic Use and Severe COVID-19: Avoiding the Impact of Age in a Real-World Data Study.Int J Neuropsychopharmacol. 2024 Apr 1;27(4):pyae020. doi: 10.1093/ijnp/pyae020. Int J Neuropsychopharmacol. 2024. PMID: 38600711 Free PMC article.
References
-
- World Health Organization (WHO), Weekly epidemiological update on COVID-19 - 4 May 2022. 2022 https://www.who.int/publications/m/item/weekly-epidemiological-update-on....
-
- WHO. WHO Classification of Omicron (B.1.1.529): SARS-CoV-2 variant of concern. https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1..... Accessed 9 May 2022.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical